The UK has some of the best patient data available anywhere in the world, and a preeminent position in the collection of cancer data at both an individual tumour and patient level.
AstraZeneca’s Calquence has been shown to improve progression-free survival in previously untreated mantle cell lymphoma (MCL), with an unprecedented trend towards improved overall survival